Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 16Withdrawn 3Unknown 3Terminated 3Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Uterine Cervical Neoplasms 4Breast Neoplasms 4Oropharyngeal Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymus Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1

Interventions

Carboplatin 85pembrolizumab 78Pemetrexed 68Cisplatin 56Paclitaxel 45osimertinib 41Nivolumab 40durvalumab 37Docetaxel 33atezolizumab 20Gemcitabine 18Radiotherapy 17Radiosurgery 16amivantamab 15Ipilimumab 15130-nm albumin-bound paclitaxel 14Taxes 13Specimen Handling 12Magnetic Resonance Spectroscopy 12Crizotinib 11lazertinib 9Radiation 9Immunoglobulin G 9Drug Therapy 9Disulfides 9Bevacizumab 9tislelizumab 8cemiplimab 8alectinib 8Erlotinib Hydrochloride 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Non-Small-Cell Lung × Fluorodeoxyglucose F18 × Clear all
NCT04214262 2026-05-13

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
480 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡